Finoriq research workspace
Acumen Pharmaceuticals, Inc. (ABOS) Historical Metrics
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies. Review ABOS fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Company
- Acumen Pharmaceuticals, Inc. (ABOS)
- Ticker
- ABOS
- Market Cap
- $158.5M
- Latest Price
- $2.195
- Industry
- Biotech & Pharma
Acumen Pharmaceuticals, Inc. (ABOS) Current Valuation Metrics
Static valuation preview for Acumen Pharmaceuticals, Inc. (ABOS). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -57.8% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -53.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.24x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.